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Abstract
Transglutaminase 2 (TG2) is a multifunctional enzyme that has guanine nucleotide binding and GTP hydrolyzing activity in
addition to its transamidating function. Studies show that TG2 is a player in mediating cell death processes. However, there
is far from a consensus about the role of this enzyme in cell death processes as it appears to be dependent upon the cell
type, stimuli, subcellular localization and conformational state of the enzyme. The purpose of this study was to dissect the
role of TG2 in the cell death processes. To this end, we created and characterized 4 distinct point mutants of TG2, each of
which differs from the wild type by its conformation or by lacking an important function. We also prepared these mutants as
nuclear targeted proteins. By overexpressing mutant or wild type forms of TG2 in HEK 293 cells, we investigated the
modulatory role of the protein in the cell death process in response to three stressors: thapsigargin, hyperosmotic stress
and oxygen/glucose deprivation (OGD). All of the TG2 constructs, except the R580A mutant (which cannot bind guanine
nucleotides and is therefore more prone to exhibit transamidating activity), either did not significantly affect the cell death
processes or were protective. However in the case of the R580A mutant, cell death in response to high thapsigargin
concentrations, was significantly increased. Intriguingly, nuclear localization of R580A-TG2 was sufficient to counteract the
pro-death role of cytoplasmic R580A-TG2. In addition, nuclear localization of TG2 significantly facilitated its protective role
against OGD. Our data support the hypothesis that the transamidation activity of TG2, which is mostly quiescent except in
extreme stress conditions, is necessary for its pro-death role. In addition, nuclear localization of TG2 generally plays a key
role in its protective function against cell death processes, either counteracting the detrimental effect or strengthening the
protective role of the protein.
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Introduction
Transglutaminase 2 (TG2, EC 2.3.2.13) is a member of the
transglutaminase (TG) family that catalyzes thiol- and Ca
2+-
dependent transamidation reactions. The transamidation reaction
that is catalyzed by the TG family is the formation of a covalent
bond between the c-carboxamide group of a peptide bond
glutamine residue and a primary amine group [1]. TG2 is the
most ubiquitously expressed and is the most studied member of the
family. In addition to its transamidating activity, it binds and
hydrolyzes GTP [2]. Ca
2+ and guanine nucleotide binding
inversely regulate the transamidating activity of TG2; that is,
TG2 is only active as a transglutaminase when bound to Ca
2+ and
inactive when bound to the guanine nucleotides [3]. However, in
the guanine nucleotide bound form, TG2 is proposed to be
involved in regulating signal transduction by acting as a G-protein
which transduces a signal from several different receptors to
phospholipase C-d1 [4]. Moreover, recent developments shows it
truly is a multifunctional protein as it is demonstrated to function
as a protein disulfide isomerase (PDI) [5] and protein kinase [6,7].
Lastly, it has been shown to interact with certain proteins with no
clear evidence of enzymatic activity playing a role, which indicates
that it also can act as a protein scaffold [8,9].
The structural basis for its multifunctionality is partly clear since
the crystal structure of TG2 is available both in its GDP bound
closed conformation and in an inhibitor bound open conformation
[10,11]. However, none of the crystals include bound Ca
2+;
therefore Ca
2+-binding residues are not known with certainty,
although structure prediction and site directed mutagenesis studies
have suggested at least 3 different Ca
2+-binding sites [12,13]. The
prevailing view is that the binding of the Ca
2+ ions and guanine
nucleotides have opposite effects on the transamidating function of
the enzyme; the former potentiates this function while the latter
attenuates it [3,14]. However, TG2 has a much higher affinity for
the guanine nucleotides than it has for Ca
2+ [12]. Therefore, it has
been proposed that in the cell, the transamidating activity of TG2
is usually latent and only is expressed during processes such as
apoptosis or differentiation. This view is further strengthened by
the recent observation that even extracellular TG2 is not active as
a transamidating enzyme in normal physiological conditions,
although it is activated during wound healing [15], which
represents a more pathological condition. However, previous
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extracellular TG2 might be important for the normal physiological
processes such as extracellular matrix stabilization [16,17]. These
seemingly controversial observations on the activity state of
extracellular TG2 suggest that there are other, yet unidentified,
factors that can regulate transamidating function of TG2 in
addition to Ca
2+ ions and the guanine nucleotides [15].
The catalytic site of transamidating activity is composed of the
catalytic triad characteristic of cysteine proteases; cysteine 277
(C277), histidine 335 (H335) and aspartate 358 (D358) are the
critical residues for transamidating activity in human TG2 [10].
The cysteine to serine mutation at the position 277 (C277S) has
been extensively used to inactivate the transamidation function of
TG2 [18,19]. Although it knocks out all transamidating activity, it
also results in a conformation change which greatly impairs the
guanine nucleotide binding capability as well [10,20]. In addition
to the catalytic triad, a conserved tryptophan residue (W241) is
also critical for the transamidating activity and mutating this
residue to an alanine (W241A) knocks down all transamidating
activity without any effect on guanine nucleotide binding [21].
The guanine nucleotide binding pocket, on the other hand, is
composed of at least ten residues; however, one arginine residue
(R580) interacts with the guanine nucleotide at several points and
its mutation to alanine (R580A) results in the almost complete loss
of guanine nucleotide binding activity without any significant
effect on the transamidating activity [20,22]. Finally, TG2 is
proposed to have open and closed conformers, with notably
distinct features [3,11]. The closed form is used as an equivalent to
the GTP/GDP bound form, which is predicted to be more
compact than the open conformer. The tyrosine residue at the
position 516 (Y516) is critical to attaining the closed conformation
and mutation of this residue to phenylalanine (Y516F) renders
TG2 more prone to an open conformation [3,11].
A primary role of TG2 in the cell is to modulate cell death
processes. However the function of TG2 in cell death is complex
and context specific. Depending on the stressor and cell type, TG2
can either facilitate or ameliorate cell death processes
[12,18,22,23,24,25,26,27]. This complexity may be due to its
different activities, cellular localization, different isoforms or
different conformations [18,28,29,30]. There are studies suggest-
ing that transamidating activity is required for its protective role
[31], as well as the studies showing that transamidating activity
actually facilitates apoptosis [18]. There is substantial evidence
suggesting that guanine nucleotide binding renders TG2 more
protective [22]. However, there is controversy as to whether the
protection is due to guanine nucleotide binding per se or suppressed
transamidating activity as a result of this binding, an issue that
remains unresolved.
In this study we investigated the TG2 – cell death relationship
focusing on three of these variables: i) its conformation/activity
state, ii) localization (nuclear or cytoplasmic) and iii) the type of
stressor used to induce cell death. This was accomplished by
generating 4 different point mutations each of which has a unique
effect on the conformation/activity state of the protein with and
without a nuclear localization signal (NLS) and measuring how
they modulate cell death in response to three distinct stressors:
hyperosmotic stress, thapsigargin and oxygen/glucose deprivation.
In our models the transamidating activity of TG2 was very low
under resting conditions; and as long as the protein was silent in
terms of transamidating activity, it was either neutral or protective
against cell death. However, the R580A mutation which resulted
in an increase in in situ transamidating activity also facilitated
TG2’s role as a pro-death protein. Nuclear localization of TG2,
especially when it was not active as a transamidating enzyme,
almost invariably resulted in an attenuation of cell death. The
Y516F mutation causes similar changes in the guanine nucleotide
binding and transamidating activity characteristics of the protein
as R580A, although the latter mutation is a considerably more
potent mutation than the former. Very intriguingly, for certain
stressors, the cell death profile of Y516F mutant was similar to that
of R580A. Overall, this study strongly suggests that the major
function of TG2 in the cell does not involve its transamidating
activity and that it attenuates cell death in a transamidating
activity independent manner when localized to the nucleus.
Results
Expression of TG2 constructs in HEK 293A cells
The relative expression levels of the different TG2 constructs
were determined by immunoblotting. To equalize expression
levels of the TG2 the amount of transfected plasmid DNA was
adjusted for each construct (Fig. 1). The untagged TG2 constructs
migrated at approximately 77 kDa whereas the NLS/myc tag
decreased the electrophoretic mobility of the protein (Fig. 1a).
Subcellular localization of TG2 in transfected cells by
different TG2 constructs
The subcellular localization of the untagged and NLS-tagged
TG2 constructs was determined by separating transfected cells into
cytosolic and nuclear fractions. The purity of cytosolic and nuclear
fractions was demonstrated by immunoblotting for histones
(nuclear proteins) and a-tubulin (a cytosolic protein) (Fig. 1b&c).
As expected, only trace amounts of TG2 were found in the nucleus
with the untagged TG2 transfected cells (Fig. 1b), as it has
previously been shown that endogenous or exogenous TG2 is
mainly cytoplasmic [32]. The NLS tagged TG2 constructs,
however, were found by densitometric analysis predominantly in
the nucleus (approximately 80%) (Fig. 1c). Notably, none of the
mutations significantly changed the subcellular localization of
TG2 (Fig. 1b&c).
The effect of the mutations on the affinity of TG2 for
guanine nucleotides
To determine the effect of the mutations on TG2, a GTP
agarose pull down assay was used [33]. The cells were transfected
with the untagged TG2 constructs and collected 24 h later. In
order to evaluate the relative affinities of the TG2 constructs for
GTP, we used two different stringency conditions for this assay. In
the low stringency conditions we used 150 mM NaCl and 0.1%
Triton-X and in the high stringency conditions we used 300 mM
NaCl and 0.5% Triton-X. At high stringency, only wild type TG2
and W241A-TG2 effectively bound to the GTP-agarose; which
demonstrates that the W241A mutation has no effect on the
guanine nucleotide binding ability of the protein (Fig. 2). However,
at low stringency, in addition to wild type and W241A-TG2;
Y516F-TG2 and, to a much lesser extent, C277S-TG2 was found
to bind to GTP agarose (Fig. 2). The results from the GTP-agarose
pull down assay suggest that the guanine nucleotide binding
affinities of TG2 constructs are as follows: wild type=-
W241A.Y516F.C277S..R580A. These findings are in agree-
ment with previous studies [3,20,34].
The effect of the mutations on the in situ transamidating
activity of TG2
In situ transamidating activities of the untagged TG2 constructs
were determined. Twenty-four hours post-transfection no transa-
midating activity was detected in basal conditions for any of the
TG2 Impacts Cell Death
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2+
concentrations and activate TG2. In the presence of 1 mM
ionomycin an approximately 3 fold increase was observed in the
transamidating activity of R580A-TG2 transfected cells (Fig. 3a).
This result is as expected as this mutation significantly decreases
the affinity of TG2 for guanine nucleotides (Fig. 2), the most well
known intracellular TG2 inhibitors [34]. At an ionomycin
concentration of 1.5 mM, wild type TG2 and Y516-TG2
transfected cells also exhibited transamidating activity. At this
concentration of ionomycin wild type, R580A-TG2 and Y516F-
TG2 transfected cells all exhibited in situ transamidating activity
that was approximately 6 fold over vector control (Fig. 3a). No
transamidating activity was detected with the W241A and C277S
mutations as expected (Fig. 3a).
Figure 1. Expression and Subcellular Localization of TG2 constructs. Representative immunoblots of cell lysates from HEK 293A cells which
were transiently transfected with TG2 constructs. (a) Expression of TG constructs. Lysates were blotted for TG2. untagged: TG2s without an NLS tag,
except size control (which is NLS-tagged wild type). NLS-tagged: TG2s with NLS tag, except lane size control (which is untagged wild type). (b)
Subcellular localization of untagged TG2 variants. Twenty four hours posttransfection cells were separated into nuclear and cytosolic fractions and
were blotted for TG2, histones and tubulin proteins. Histone (nuclear marker) and tubulin (cytosolic marker) blots show the purity of the fractions.
TG2 blot shows that untagged TG2 variants are localized almost exclusively to the cytosol and none of the mutations has a significant effect on the
localization of TG2. (c) Subcellular localization of NLS-tagged TG2 variants. Twenty four hours posttransfection cells were separated into nuclear and
cytosolic fractions and were blotted for TG2, histones and tubulin proteins. TG2 blot shows that more than 80% of the total amount of NLS-tagged
TG2 variants are localized to the nucleus and none of the mutations has a significant effect on the localization of NLS-TG2. 10 mg of protein was
loaded in each well.
doi:10.1371/journal.pone.0006123.g001
Figure 2. GTP Binding of TG2 Mutants. Immunoblot showing GTP binding of different TG2 constructs. (a) expression levels of TG2 constructs.
10 mg of protein was loaded in each well. Pulldown experiments were performed with GTP agarose using low (b) and high (c) stringency conditions
to evaluate the strength of binding between TG2 and GTP.
doi:10.1371/journal.pone.0006123.g002
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transamidating activity of TG2
To evaluate total transamidating activity, in vitro transamidat-
ing activities were measured in lysates collected from the cells
transfected with each of the untagged TG2 constructs. In this
assay, increasing concentrations of Ca
2+ were used to determine
the relative activation state of each of the TG2 constructs. In vitro
transamidating activities of wild type TG2, R580A-TG2 and
Y516F-TG2 were expressed as a fold increase over vector control
lysates. The assay was conducted at various Ca
2+ concentrations in
the range of 0–10 mM, but only the data for 0, 2 and 6 mM added
Ca
2+ are shown (Fig. 3b). The activities of W241A-TG2 and
C277S-TG2 are not shown since they exhibited no detectable in
vitro transamidating activity. The results from the in vitro
transamidating activity measures were similar to those of the ones
obtained with in situ transamidating assay (Fig. 3b). In the absence
of any exogenously added Ca
2+, there was no detectable activity.
Addition of 2 mM Ca
2+ was sufficient to fully activate R580A-
TG2 (approximately 8 fold over vector control) and increase
transamidating activity in the lysates of Y516F-TG2 transfected
cells approximately 3 fold over vector control. However at 2 mM
Ca
2+, wild type-TG2 exhibited no detectable activity. The
addition of 6 mM exogenous Ca
2+ was sufficient to fully activate
the transamidating activity (approximately 8 fold over vector
control) for all of TG2 constructs that were catalytically active:
wild type, R580A-TG2 and Y516F-TG2. These results indicate
that the Y516F mutation compromises guanine nucleotide binding
which results in a lower Ca
2+ threshold for the activation of
transamidating activity compared to wild type TG2.
Cytosolic R580A-TG2 promotes thapsigargin-induced
toxicity in HEK 293A cells
HEK 293A cells were transfected with the TG2 constructs and
24 h later they were treated with 15 mM thapsigargin. The effect
of thapsigargin on cell viability was determined using three
different measures; LDH release, a resazurin to resorufin
Figure 3. Transamidating activity of TG2 variants. Graphs showing in situ (a) and in vitro (b) transamidating activities of different TG2 mutants
as a function of ionomycin concentration (mM) in the cell culture medium (a) or calcium ion added (mM) to the reaction mixture (b) (N=3). Results
are shown as mean+/2SE *p,0.05, **p,0.01, ***p,0.005.
doi:10.1371/journal.pone.0006123.g003
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of thapsigargin treatment, approximately 25% of total LDH was
released to the media in vector control cells (Fig. 4a). Untagged
R580A-TG2 significantly increased LDH release to approximately
50% of the total LDH (Fig. 4a). The toxic effect of the untagged
R580A-TG2 was confirmed by the caspase-3 assay, as well. After
4 h of thapsigargin treatment, a 4–5 fold increase in caspase-3
activity was observed in vector control cells and an approximately
8 fold increase in untagged R580A-TG2 transfected cells (Fig. 4c).
These findings are particularly interesting given that thapsigargin
treatment of R580A-TG2 transfected cells results in a slight but
significant increase in in situ transamidating activity, while this is
not the case for the other TG2 constructs (data not shown, see
discussion). These results suggest that the increase in the
transamidating activity of R580A-TG2 in response to thapsigargin
treatment may result in facilitation of cell death in a caspase-
dependent manner. The resazurin assay, which measures the
reducing potential of the cell, revealed no significant differences
between R580A-TG2 transfected cells and vector control cells, in
response to thapsigargin (Fig. 4b). Interestingly, both untagged and
NLS-tagged W241A-TG2 significantly attenuated the loss of
reducing potential in response to thapsigargin compared to vector
cells as measured by resazurin to resorufin conversion (Fig. 4b).
These results indicate that depending on the conformation and
activity state, TG2 can differentially affect distinct aspects of cell
death processes.
Cytosolic W241A-TG2 protects against serum starvation
and thapsigargin-induced toxicity in HEK 293TN cells
To examine the effect of TG2 on cell viability in the absence of
pronounced cell death, HEK 293TN cells were transfected with
the TG2 constructs and 24 h later they were transferred to serum
free media and incubated with or without 2.5 mM thapsigargin.
After 24 h of serum starvation alone or serum starvation combined
with thapsigargin treatment, cell viability was measured using the
resazurin assay. Serum starvation decreased the cell viability to
,70% in vector control cells compared to non-serum-starved cells.
Cytoplasmic W241A-TG2 mutant almost completely counteract-
Figure 4. TG2 can either protect against or facilitate thapsigargin induced cell death in HEK 293A cells depending on its
conformation and its localization. (a) LDH release after 9 h of 15 mM thapsigargin treatment. LDH release is significantly increased in HEK 293A
cells which express R580A-TG2 without an NLS tag. (N=3). (b) Cell viability determined by the resazurin assay after 10 h of 15 mM thapsigargin
treatment. Metabolic activity is significantly increased in HEK 293A cell which express W241A-TG2 with or without an NLS tag. (N=4) (c) Caspase-3
activity after 6 h of 15 mM thapsigargin treatment. Caspase-3 activity is significantly increased in HEK 293A cells which express R580A without an NLS
tag. (N=3). Results are shown as mean+/2SE *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0006123.g004
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,95% (Fig. 5). Serum starvation combined with thapsigargin had
a more severe impact on cell survival and decreased the viability to
,40%. Yet again, cytoplasmic W241A-TG2 construct significant-
ly protected against serum starvation combined with thapsigargin
treatment and increased the viability to ,55% (Fig. 5) No increase
in LDH release assay or caspase-3 activity were observed after
24 h of 2.5 mM thapsigargin treatment and/or serum starvation
(data not shown).
TG2 protects HEK 293A cells against hyperosmotic stress
in a caspase-independent manner, regardless of its
conformation and intracellular localization
After 3–4 h of 1.0 M sorbitol treatment all cells started to show
signs of apoptosis such as membrane blebbing (data not shown).
10 h of 1.0 M sorbitol treatment resulted in approximately 35%
LDH release in vector control cells. Overexpression of any of the
TG2 constructs, regardless of nuclear or cytoplasmic localization,
significantly decreased LDH release (Fig. 6a). The results of
resazurin assay, which was performed after 6 h of sorbitol
treatment, were similar to LDH release assay results, however,
the variance in the data between the constructs was more
pronounced. The results from resazurin assay show that,
hyperosmotic stress decreased the cell viability to ,40% in vector
control cells. Most of the TG2 constructs caused a significant
improvement in the viability (up to 60%–80%). However, cytosolic
R580A-TG2, cytosolic Y516F-TG2 and nuclear R580A-TG2
constructs did not increase cell viability compared to vector cells
(Fig. 6b). Interestingly, the protective effect of TG2 against
hyperosmotic stress was not due to a decrease in caspase-3 activity.
There was an approximately 3.5 fold increase in the caspase-3
activity after 6 h of sorbitol treatment compared to isosmotic
conditions in cells transfected with the TG2 constructs as well as
the empty vector (data not shown).
Nuclear localized and catalytically quiescent TG2 protects
HEK 293A cells against oxygen/glucose deprivation
(OGD) induced cell death
To induce oxygen/glucose deprivation (OGD), cells were
maintained at 0.1% oxygen in serum and glucose free media for
16 h of OGD which resulted in approximately 25% LDH release
in vector control cells (Fig. 7a). LDH release was significantly
attenuated in NLS-wild type-TG2, NLS-C277S-TG2 and NLS-
W241-TG2 transfected cells (Fig. 7a). No increase in caspase-3
activity was detected in this OGD paradigm (data not shown), and
the resazurin assay could not be used in this stress paradigm.
We have recently reported that TG2 interacts with hypoxia
inducible factor 1b (HIF1b), attenuates HIF signaling and protects
against OGD induced cell death in a different cell model [9].
Therefore we transfected an HRE reporter plasmid together with
the TG2 constructs to monitor HIF activity. The results shown in
Fig. 7b demonstrates that all NLS-tagged TG2 constructs, but not
their untagged counterparts, significantly suppressed HIF-depen-
dent transcription after 16 h of hypoxia. An NLS-tagged GFP
construct was used as a negative control to test whether
overexpressing a nonspecific protein in the nucleus was sufficient
to suppress HIF-dependent transcription. As expected, nuclear
localized GFP had no significant effect on HIF activity (data not
shown). In summary, although all of the nuclear TG2 constructs
attenuated HIF signaling, only the catalytically silent TG2 variants
(including wild type TG2 which has very low transamidating
activity except in excessive stress conditions) protected cells against
OGD-induced cell death.
Discussion
In order to understand the differential roles of TG2 in cell death
processes, we examined how TG2 regulates cell death in response
to 3 different cell stressors: hyperosmotic stress, thapsigargin and
Figure 5. Cytosolic W241A-TG2 protects against serum starvation and thapsigargin-induced toxicity in HEK 293TN cells. Cell viability
determined by the resazurin assay after 24 h of serum starvation and serum starvation combined with 2.5 mM thapsigargin treatment. Cytosolic
W241A-TG2 significantly improves metabolic activity of HEK 293TN cell both after serum starvation alone and serum starvation combined with
thapsigargin treatment. (N=3) Results are shown as mean+/2SE *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0006123.g005
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activity and conformation states of TG2 that were either untagged
or targeted specifically to the nucleus.
The transamidating activity and GTP binding behavior of the
constructs was as would be predicted based on our knowledge of
the structure and function of TG2 [3,10,11]. However, one
interesting observation was that transient transfection of R580A-
TG2 did not result in an increase in basal transamidating activity,
although increased in situ transamidating activity was observed in
response to ionomycin. Since this mutation almost abolishes
guanine nucleotide binding activity — the most well known
intracellular TG2 inhibitors — basal increases in transamidating
activity in R580A-TG2 transfected cells may have been expected.
Indeed, we [20] and others [34] have reported increases in basal
transamidating activity in cells that were transfected with R580A-
TG2. This may be due to methodological differences, as in the
current study we used an order of magnitude less of the 5-
(biotinamido)pentylamine (BAP) (acyl acceptor in the transamidat-
ing reaction) to measure in situ transamidating activity since at
higher concentrations non-specific background activity increases.
Another possible explanation for these seemingly contradictory
results would be the fact that guanine nucleotides and Ca
2+ ions
are probably not the only regulators of the transamidating activity
of TG2 [3,12,20].
It should also be noted that although both the C277S and
W241A mutations knock out transamidating activity, there are
distinct differences between the two constructs. The former one
has been used in numerous studies as a catalytically inactive form
of TG2 [1,19,35]. However, it is now clear that mutation of C277
does not only abolishes transamidating activity but also signif-
icantly reduces guanine nucleotide binding likely due to a
significant change in the overall structure of the protein [3,20].
Therefore, in this study we also used the W241A mutant, which
has no detectable effect on GTP binding (Fig. 2), in addition to the
C277S mutant, in order to determine whether these two mutations
have differential effects on the role of TG2 in cell death. Our data
shows that C277S-TG2 and W241A-TG2 do not differ in their
ability to protect against most of the stressors suggesting that
guanine nucleotide binding is not a major factor. However, there
is an exception to this general conclusion. W241A-TG2
significantly improved viability after prolonged treatment with
lower concentrations of thapsigargin treatment and serum
starvation as measured by the resazurin assay, whereas C277S-
TG2 was not protective (see below). It has previously been
reported that GTP binding of TG2 in certain paradigms is
important for its role in cell survival/death [22]. Our results
support the conclusion that guanine nucleotide binding in certain
stress conditions may play a role in the protective function of TG2.
Overall, these data shows that the prosurvival effect of TG2 is
strongest when it has no transamidating activity and efficiently
binds to guanine nucleotides. This information might be valuable
for any therapeutic approach which might target or exploit the
pro-survival function of TG2.
Thapsigargin is a very potent inhibitor of the sarco/endoplas-
mic reticulum Ca
2+ ATPase (SERCA) pump and empties ER Ca
2+
stores while increasing cytosolic Ca
2+ concentrations. In addition
to the increased cytosolic Ca
2+ effect, it also impairs the ER
functioning and triggers the unfolded protein response (UPR)
pathway (ER-stress). Given the fact that the concentration of
thapsigargin used in HEK 293A cells was 15 mM, the effect of this
drug might not be restricted to SERCA inhibition. For instance, in
a study conducted on isolated mitochondria, the same concentra-
tion of thapsigargin induced maximal mitochondrial swelling and
MPTP opening independent of extra-mitochondrial Ca
2+ concen-
trations [36], which would result in Ca
2+ release. Indeed,
thapsigargin concentrations used in HEK 293A cells caused a
moderate (1.5–2 fold) increase in in situ transamidating activity in
R580A-TG2 and NLS-R580A-TG2 transfected cells (data not
shown) clearly indicating a sustained increase in intracellular Ca
2+
levels. Intriguingly, LDH release and caspase-3 activity were
significantly increased in R580A-TG2 transfected cells but not in
NLS-R580A-TG2 transfected cells. This suggests that increased
transamidating activity in the cytosol facilitates cell death, but in
the case of NLS-R580A-TG2 the amount of active TG2 in the
Figure 6. TG2 protects HEK 293A cells from hyperosmotic stress, independent of its localization and conformation. (a) LDH release
after 10 h of 1.0 M sorbitol treatment. LDH release is significantly decreased in HEK 293A cells which express TG2 regardless of the conformation state
or its subcellular localization (N=5). (b) Cell viability determined by the resazurin assay after 6 h of 1.0 M sorbitol treatment. Hyperosmotic stress-
induced decreases in metabolic activity are significantly attenuated by TG2 constructs except for untargetted R580A-TG2, untargetted Y516F-TG2 and
nuclear targetted R580A-TG2 (N=4). Results are shown as mean+/-SE *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0006123.g006
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majority (approximately 80%) is located in the nucleus. Alterna-
tively, increased localization of the protein to the nucleus might be
counteracting the detrimental impact of the increase in cytoplas-
mic transamidating activity. This alternative is especially plausible
since it has been shown that nuclear localized transamidating –
inactive TG2 protects against apoptosis induced by thapsigargin
[28]. The resazurin assay measures the reducing capacity of a
viable cell, therefore is sensitive to the redox state of the
intracellular milieu. The results of this assay suggests that
W241A-TG2 and NLS-W241A-TG2 are protective against
thapsigargin-induced cell death in HEK 293A cells, although this
protection is not reflected in LDH release and caspase-3 activity
assays. The reason of this seemingly contradictory result might be
the fact that TG2 has more than one intervention point in the cell
death process. Since each assay measures a different aspect of cell
death, a multifunctional protein such as TG2 might differentially
modulate these different aspects and give contradictory results in
different assays.
As mentioned above, 15 mM is a rather high concentration of
thapsigargin and thus it is possible that there could be some off
target effects; some of which might be relevant to TG2 (such as a
possible decrease in the intracellular GTP levels). Therefore we
investigated how TG2 impacted cell viability at concentrations of
thapsigargin that did not result in significant cell death. To this
end, we treated HEK 293A cells with thapsigargin at concentra-
tions of 1 to 5 mM for 24 h. However this treatment resulted in no
decrease in cell viability with any assay (data not shown). However,
HEK 293TN cells did show a significant loss of cell viability as
determined by the resazurin assay when treated with 2.5 mM
thapsigargin treatment for 24 h in serum free conditions. Since the
concentration of the thapsigargin used was lower (2.5 mM),
considerably longer incubation periods were needed (24 h) to see
a significant decrease in cell viability, compared to the 9–10 h of
treatment with 15 mM thapsigargin in HEK 293A cells. However,
it became clear that serum starvation alone significantly attenuated
the viability of HEK 293TN cells unlike HEK 293A cells, most
probably due to (i) increased incubation periods and (ii) a greater
sensitivity of HEK 293TN cells to stressors. As shown in Fig. 5,
cytoplasmic W241A-TG2 significantly improved metabolic activ-
ity in HEK 293TN cells as measured by resazurin assay upon
serum starvation and serum starvation combined with 2.5 mM
thapsigargin, although no effect on LDH release or caspase
activity was observed with this treatment paradigm.. Overall, it
seems plausible to speculate that W241A-TG2 facilitates cell
viability perhaps by improving the metabolic activity of the cell, as
indicated by the improvement in the reduction of resazurin and
the fact that TG2 has been found associated with mitochondria
[37] This role is probably distinct from the more frequently
observed protective role of nuclear TG2.
The osmolarity of the bodily fluids are under tight regulation
since sustaining isosmolar conditions is essential for the normal
functioning of the cells. Under normal physiological conditions,
only a small subset of cells is exposed to hyperosmotic stress, such
as the endothelial cells of the Bowman’s capsule of kidney.
However, some pathological conditions, such as ischemia could
result in the cells being subjected to osmotic stress [38]. In contrast
to the results in human neuroblastoma SH-SY5Y cells stably
expressing TG 2 [18], we could not detect an increase in in situ
transamidating activity in any of our wild type or mutant TG2
transfected cells upon hyperosmotic stress (data not shown).
Differences in transamidating activity measurement methodology,
cell types and stable overexpression in comparison to transient
transfection of TG2 may explain the lack of transamidating
activation in response to hyperosmotic stress. Very intriguingly, in
that study caspase-3 activation and nuclear condensation were
significantly increased in wild-type TG2 cells, compared to
C277S-TG2 and vector control cells. However in the current
study, caspase-3 activation was not altered by any of the TG2
constructs. Overall, these results suggest that TG2-mediated
enhancement of caspase-3 is dependent on its transamidating
activity. In contrast to the findings with caspase-3, all of the TG2
constructs, regardless of nuclear or cytoplasmic localization,
significantly decreased LDH release in response to hyperosmotic
challenge. These results are also in line with that of above-
mentioned study [18] in which both active and inactive forms of
Figure 7. Nuclear targeted and transamidating inactive TG2 protects HEK 293A cells from oxygen/glucose deprivation triggered
cell death independent of HIF signaling. (a) LDH release after 16 h of oxygen/glucose deprivation (OGD). LDH release is significantly decreased
in HEK 293A cells which express wild type-TG2, C277S-TG2 or W241A-TG2 with an NLS tag upon oxygen/glucose deprivation. (N=5) (b) HRE
luciferase activity after 16 h of 0.1% oxygen treatment. All nuclear targeted TG2 variants significantly decreased hypoxia responsive gene
transcription whereas none of the untargeted TG2 variants had a significant effect. Results are shown as mean+/2SE *p,0.05, **p,0.01.
doi:10.1371/journal.pone.0006123.g007
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findings argue for a caspase-independent protection mechanism.
Similarly, most but not all constructs were protective in the
resazurin assay. This small discrepancy between the results of
LDH release assay and resazurin assay might be explained by the
fact that these assays were performed at different time points. It is
also notable that the constructs (R580A and Y516F) that were not
protective in the resazurin assay exhibited transamidating activity
at lower Ca
2+ concentrations than wild type-TG2. Although we
did not detect any increase in the in situ transamidating activity
upon sorbitol treatment in R580A-TG2 and Y516F-TG2
transfected cells, it should be noted that the detection limit of
the assay is rather modest. An undetectable increase in
transamidating activity in R580A-TG2 and Y516F-TG2 trans-
fected cells might counteract the protection.
TG2 protects rat primary cortical neurons and SH-SY5Y
neuroblastoma cells against OGD-induced cell death, possibly
through its interaction with hypoxia inducible factor 1 beta
(HIF1b) and suppression of HIF signaling [9]. Transient
transfection of the TG2 constructs did not suppress HIF signaling
when expressed as predominantly as a cytosolic protein. However
when expressed with an NLS tag, regardless of the mutation, TG2
significantly attenuated HIF signaling in hypoxia. In addition, wild
type-TG2, C277S-TG2 and W241A-TG2 constructs protected
the cells against OGD significantly only when they were targeted
to nucleus. NLS-R580A-TG2 and NLS-Y516F-TG2 constructs,
while successfully suppressing HIF signaling, failed to protect cells
against OGD. It should be noted that these are the mutations that
allow TG2 to be activated at lower Ca
2+ concentrations and this
may be a contributing factor to their diminished ability to protect
against OGD. Although no increases in transamidating activity
were detected after OGD with any of the constructs (data not
shown), as discussed above, it is possible that there was
undetectable or substrate specific increase in transamidating
activity which could counteract the protection brought by HIF
suppression. In addition to this, when TG2 was not targeted to the
nucleus, the same TG2 mutants (i.e., wild type-TG2, C277S-TG2
and W241A-TG2) tended to confer protection without reaching
statistical significance. These observations all point to the same
conclusion: TG2 in the nucleus, most probably through its
scaffolding function, suppresses HIF signaling. This suppression
can only partially contribute to the protective role of TG2 against
OGD induced cell death.
The role of TG2 in cell demise is extremely controversial. There
are reports suggesting that transamidating activity of TG2 can be
detrimental [18] as well as protective [31]. Other studies have
provided evidence that transamidating activity is not important in
the context of cell death but it is guanine nucleotide binding
activity that determines the role of TG2 in apoptosis [22]. In
addition, the protein-protein interactions or scaffolding function of
TG2 was shown to be extremely important for cell death-survival
decisions, as well [39]. There is also evidence suggesting that the
subcellular localization [28] or the type of the stressor [18]
determines whether TG2 exacerbates or prevents death. Lastly, it
has been reported that in certain stress conditions intronic read
throughs of TG2 occur resulting in shortened forms of the protein
with unique C-termini [30] which have been reported to be more
pro-apoptotic than full length protein [29]. Interestingly, the pro-
apoptotic role of these variants might be relevant neither to the
transamidating activity nor to the guanine nucleotide binding
capacity, but to the fact that they render TG2 more prone to an
aggregate forming conformation [29].
The data in this study clearly show that TG2 can differentially
influence the fate of the cell depending on the type of stressor, the
activity state, conformation and localization of the enzyme.
Furthermore, even in response to the same stressor, TG2
differentially modulates specific aspects of the cell death pathway,
even in opposing directions. Due to the multifactorial effect of
TG2 on cell death pathways, specific conclusions about the role of
this protein in cellular death remain elusive. Nonetheless, by close
examination of our results it is possible to extract some tangible
generalizations (see Figure 8). Our results support the predominant
hypothesis that transamidating activity of TG2 is generally kept
very low under resting conditions. The R580A mutation facilitated
the pro-apoptotic role of TG2 by allowing it to express
transamidating activity in response to certain stressors, as it is
usually an inactive and protective protein. Nuclear localization of
catalytically active cytosolic TG2 was sufficient to counteract its
pro-death role. Similarly nuclear targeting of inactive TG2
variants reinforced their protective effect in most cases. However,
in certain cases, cytosolic inactive TG2 which strongly binds
guanine nucleotides improved the metabolic profile of the cell
more efficiently than the nuclear TG2 when the stress was mild
and did not result in overt cell death. Overall, our data strongly
suggest that the physiological function of TG2 is likely not
primarily as a transamidating enzyme but rather as a scaffolding or
adaptor protein, and that only in certain types of extreme stress
conditions when death is unavoidable is the transamidating
activity increased possibly to facilitate a more organized cell death
process. Otherwise, TG2 is mostly protective.
Materials and Methods
Constructs
The untagged TG2 constructs were cloned into pcDNA 3.1 (+)
(Invitrogen); pShooter pCMV/nuc/myc vector (Invitrogen) was
used to make the NLS-tagged TG2 constructs. Untagged wild
type-TG2, C277S-TG2 and R580A-TG2 have been described
previously [20,40]. W241A-TG2 and Y516F-TG2 were prepared
for this study using the pcDNA-wildtype-TG2 construct as a
template and the GeneEditorTM in vitro Site-Directed Mutagen-
esis System (Promega). The primer used to make the W241A-TG2
construct was 59- GCT GGG ACG CGC GGA CAA CAA CTA
C- 39 and for the Y516F-TG2 construct was 59- CTG TGC CCG
CAC CGT CAG CTT CAA TGG GAT CTT GG- 39.
Mutagenesis was carried out according to the manufacturer’s
instructions and the presence of the mutations was confirmed by
sequencing. NLS tagged constructs were prepared as described
previously [28]. The resulting NLS-tagged constructs were verified
by sequencing.
Cell Culture
HEK 293A cells were cultured in Dulbecco’s modified Eagle’s
medium (Irvine Scientific) supplemented with 5% fetal bovine
serum (HyClone), 2 mM L-glutamine (Invitrogen, Life Technol-
ogies, Inc.), 100 mg/ml streptomycin (Invitrogen, Life Technolo-
gies, Inc.) and 100 units/ml penicillin (Invitrogen, Life Technol-
ogies, Inc.). For HEK 293TN cells, the plates were coated with
0.1 mg/mL poly-L-lysine in PBS 24 h prior to use. The plates
were rinsed with PBS once immediately prior to use and the cells
were cultured on these plates in Dulbecco’s modified Eagle’s
medium/F12 medium (50:50) (Irvine Scientific) supplemented
with 5% bovine growth serum (HyClone), 2 mM L-glutamine,
100 mg/ml streptomycin and 100 units/ml penicillin. Cells were
grown in a humidified atmosphere containing 5% CO2 at 37uC.
Transient transfections were carried out using FuGENE 6 reagent
(Roche Applied Science) or Lipofectamine 2000 (Invitrogen)
according to the manufacturers’ instructions.
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24 h after transfection, cells were transferred to serum-free
media in which the treatments performed. For thapsigargin
treatment, HEK 293A cells were treated with 15 mM thapsigargin
(Alexis) in serum-free medium for 10 h (LDH release assay) or 6 h
(caspase-3 and resazurin assay) at 37uC. HEK 293TN cells were
treated with 2.5 mM thapsigargin in serum-free medium for 24 h.
The thapsigargin was prepared in Me2SO and the control cells
were treated with Me2SO under the same conditions. For
hyperosmotic stress, 1.0 M sorbitol solution was prepared in
serum free media and the HEK 293A cells were treated in
sorbitol/media solution for 9 h (LDH release assay) or 6 h
(caspase-3 and resazurin assay) at 37uC. Control cells were treated
in serum free media under the same conditions. For oxygen
glucose deprivation, HEK 293A cells were transferred to serum
and glucose free Dulbecco’s modified Eagle’s medium (Irvine
Scientific) and incubated in a humidified atmosphere containing
5% CO2 and 0.1% oxygen at 37uC for 16 h. Control cells were
treated in serum free glucose containing normal DMEM in a
humidified atmosphere containing 5% CO2 and ambient oxygen
at 37uC. For the HRE luciferase reporter assay cells were
transferred to serum free media and incubated in a humidified
atmosphere containing 5% CO2 and 0.1% oxygen at 37uC for
16 h. Immediately after the incubation the activity of the reporter
was measured. Control cells were treated in serum free media in a
humidified atmosphere containing 5% CO2 and ambient oxygen
at 37uC.
Nuclear Fractionation
Nuclear fractionation studies were conducted as previously
described [28] with slight modifications. Briefly, HEK 293A cells
were washed twice, harvested in ice cold PBS and the cell pellets
were resuspended in lysis buffer (10 mM Tris, pH 7.5, 10 mM
NaCl, 3 mM MgCl2, 0.05% Nonidet P-40, 1 mM EGTA) with
protease inhibitors (0.1 mM phenylmethylsulfonyl fluoride, and
10 mg/ml of each of aprotinin, leupeptin, pepstatin A) by
triturating followed by centrifugation at 380 6g for 5 min at
4uC. The supernatants were collected and used as the cytosolic
Figure 8. Hypothetical model of the role of TG2 in cell death/survival paradigm. Depending on the stressor type and intensity, TG2 can
facilitate or counteract cell death process. Some stressors, such as OGD, trigger nuclear translocation of TG2 through an unknown mechanism, where
TG2 mainly promotes survival processes possibly through intervening transcriptional machinery by scaffolding certain transcription factors (TF), co-
activators (coact) or co-repressors (corep). Conversely, some stressors dramatically decrease the guanine nucleotide to calcium ratio and elevate
transamidating activity of TG2. The increase in the transamidating activity generally means that the death decision has been made and the
transamidating function of TG2 helps to execute the death process.
doi:10.1371/journal.pone.0006123.g008
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wash buffer (30 mM sucrose, 10 mM Pipes, pH 6.8, 3 mM
MgCl2, 1 mM EGTA, 25 mM NaCl) with protease inhibitors.
The crude nuclei were overlaid on the top of 0.7 M sucrose with
protease inhibitors, and spun at 1200 6g for 10 min at 4uC. The
pellets were collected and resuspended in buffer B (300 mM
sucrose, 10 mM Pipes, pH 6.8, 3 mM MgCl2, 1 mM EGTA,
25 mM NaCl, 0.5% Triton X-100) with protease inhibitors and
used as the nuclear fractions. The proteins were visualized by
immunoblot analysis.
Immunoblotting
Cells were rinsed in ice-cold phosphate-buffered saline (PBS)
and collected in lysis buffer, containing 0.5% NP-40, 150 mM
NaCl, 10 mM Tris-Cl (pH 7.4), 1 mM EGTA, 1 mM EDTA,
1 mM phenylmethylsulphonyl fluoride, 1 mM okadaic acid, and
10 mg/ml each of aprotinin, leupeptin, and pepstatin. Samples
were sonicated on ice and centrifuged at 16,000 g for 10 min.
Protein concentrations of supernatants were then determined by
the bicinchoninic acid assay with bovine serum albumin (BSA) as a
standard and samples were diluted to a final concentration of
1 mg/ml with 26reducing stop buffer (0.25 M Tris-HCl, pH 6.8,
5 mM EDTA, 5 mM EGTA, 25 mM dithiothreitol, 2% SDS,
10% glycerol, and bromophenol blue as the tracking dye). Samples
(5–25 mg of protein depending on the assay) were resolved on 10%
SDS-polyacrylamide gels, and transferred to nitrocellulose. Blots
were blocked in 5% nonfat dry milk in TBST (20 mM Tris-HCl,
pH 7.6, 137 mM NaCl, 0.05% Tween 20) for 1 h at room
temperature. The blots were then incubated overnight with a
mouse monoclonal TG2 primary antibody TG100 or CUB7402
(Lab VisionNeoMarkers, Fremont, CA, USA; 1:5,000 dilutions)
The membranes were then washed three times with TBST and
incubated with HRP-conjugated secondary antibody for 1 h at
room temperature. The membranes were rinsed three times for
30 min with TBST, followed by four quick rinses with distilled
water, and developed with the enhanced chemiluminescence as
described previously [41].
GTP-agarose pull-down assay
GTP-agarose pull-down assay was performed according to the
procedure previously described [33] with slight modifications.
Briefly, 24 h after transfection, HEK 293A cells were rinsed in ice-
cold PBS and collected in GTP-binding buffer (20 mM Tris-HCl
pH:7.5, 5 mM MgCl2, 2 mM PMSF, 20 mg/mL leupeptin,
20 mg/mL pepstatin, 10 mg/mL aprotinin plus 150 mM NaCl
and 0.1% Triton-X [for low stringency] or 300 mM NaCl and
0.5% Triton-X [for high stringency]). Samples were sonicated for
15 s and centrifuged at 13,000 g for 10 min at 4uC, and the
supernatant was collected. The protein concentration of each
supernatant was determined by the BCA assay. 100 mg of lysate
protein were incubated with 100 mL of GTP-agarose beads
(Sigma-Aldrich; equilibrated in GTP-binding buffer) in a total of
500 mL of GTP-binding buffer for 30 min at 4uC. The beads were
centrifuged at 10,000 g for 2 min and the supernatant was
retained. Then, the beads were washed three times with 1 ml of
GTP-binding buffer and the retained supernatant was incubated
with the beads for another 30 min. The beads were washed again
as described above and then incubated with the retained
supernatant overnight at 4uC. After washing seven times with
GTP-binding buffer, bound protein was eluted from the beads by
boiling them in 50 mLo f2 6reducing stop buffer. TG2 that had
bound to the GTP-agarose beads was visualized by performing
immunoblot analysis on the eluted protein.
In vitro Transglutaminase Assay
In vitro transamidating activity measurement was conducted as
described previously [18] with slight modifications. Briefly, 24 h
after transfection, HEK 293A cells were washed with ice-cold PBS
and harvested in lysis buffer which is composed of 50 mM Tris-
HCl (pH 7.5), 0.25 M sucrose, 1 mM EDTA, 0.1 mM phenyl-
methylsulfonyl fluoride, and each of aprotinin, leupeptin, and
pepstatin at a concentration of 10 mg/ml. Samples were briefly
sonicated on ice, spun at 10,000 g and 4uC for 1 min. Supernatant
was transferred to another tube and protein concentration of the
supernatant was determined using the BCA assay. Samples were
diluted to a final concentration of 2.5 mg/ml with lysis buffer.
Samples containing 250 mg protein was incubated in transamidat-
ing assay buffer containing 0.1 M Tris-HCl (pH 7.5), 10 mM
dithiothreitol, 2.5% Lubrol, 0.2 mM putrescine (nonradioactive),
1 mCi of [1,4(n)-3H]putrescine dihydrochloride, 3.0 mg/ml N,N-
dimethylcasein, 0.25 mM GTPcS and given amount of CaCl2.
Reaction mixtures were incubated for 1 h at 37uC, and the
reaction was terminated by addition of trichloroacetic acid to a
final concentration of 10% (w/v). The samples were incubated on
ice for 1 h and centrifuged at 16,000 g and 4uC for 20 min. The
supernatant was removed, and the pellet was rinsed twice with
1 ml of 5% (w/v) trichloroacetic acid, then 250 mL of 0.25 M
NaOH was added to each tube. The samples were incubated at
100uC for 10 minutes, or until the pellet is completely dissolved,
by intermittent and vigorous mixing. The radioactivity emitted
from bound [3H]putrescine was quantitated by liquid scintillation
using a Beckman LS6500 scintillation counter, and TG activity
was calculated after background subtraction as fold increase over
the radioactive reading obtained from the lysate of empty vector
transfected cells.
In situ Transglutaminase Assay
In situ transamidating activity measurement was conducted as
described previously [42] with slight modifications. Briefly, 24 h
after transfection of HEK 293A cells, normal growth media was
changed to fresh growth media with 5% FBS containing given
amount of ionomycin (0–1.5 mM) and 0.1 mM 5-(biotinamido)-
pentylamine (BAP) (Pierce). 3 h later, cells were collected in media,
pelleted, washed once with PBS and resuspended in homogeni-
zation buffer (50 mM Tris-Cl, pH: 7.5, 150 mM NaCl, 1 mM
EDTA), sonicated on ice. In a high protein binding 96-well plate
(Falcon), 10 mg of protein was loaded in a total of 50 mL
homogenization buffer and the plate was incubated at 4uC
overnight. The next day, 200 mL of blocking buffer (5% BSA,
0.01% Tween 20 in borate saline [100 mM boric acid, 20 mM
Na-borate and 0.76 mM NaCl]) was added to each sample and
the plate was incubated at 37uC for 1 h. Each well was then rinsed
3 times with rinsing buffer (1% BSA, 0.01% Tween 20 in borate
saline) and incubated with 1 mg/mL Horseradish peroxidase
conjugated neutravidin (Pierce) in a total of 100 mL rinsing buffer
at room temperature for 1 h. The samples were washed 4 times
with rinsing buffer, and peroxidase reaction was conducted in the
dark in 200 mL of OPD buffer (0.1 M Na2HPO4, 50 mM citric
acid, 1 tablet o-phenylenediamine (Sigma Aldrich), 0.0006%
H2O2). After 20 minutes, the reaction was stopped by addition of
50 mL of 3 M HCl and read at 493 nm wavelength.
Caspase-3 activity assay
Caspase-3 activity was measured using a fluorometric assay.
Cells were plated in 60 mm plates and treatments were performed
as described above. Immediately after the treatment, cells were
rinsed once with PBS and harvested in lysis buffer (20 mM Tris,
pH 7.5, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 0.5%
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each of aprotinin, leupeptin, and pepstatin). Samples were
sonicated for 15 s and centrifuged at 13,000 rpm for 10 min at
4uC, and the supernatant was collected. The protein concentration
of each supernatant was determined by the BCA assay and the
samples were diluted to 1 mg/mL. Cell lysates (20 mg) were
incubated for 1 h at 37uC, in 200 mL of reaction buffer
[(20 mM HEPES, pH 7.5, 10% glycerol, 2 mM dithiothreitol
(DTT)], containing caspase-3 substrate (Ac-DEVD-AMC) (Alexis
Biochemicals, San Diego, CA, USA) at a concentration of 25 ng/
mL (Bijur et al. 2000). Fluorescence was measured using a
fluorescence plate reader (BioTek Synergy HT Multi-Detection
Microplate Reader) at wavelengths, excitation 360 nm and
emission 460 nm.
Lactate dehydrogenase (LDH) release assay
LDH release was measured using an LDH release assay kit
(Roche). Cells were plated in 24-well plates and treatments were
performed as described above. After the treatment was finished,
media and the cell lysates were collected and assay was performed
to assess cell viability. LDH release was measured as described
previously [18].
Resazurin Assay
Resorufin production by viable cells was determined by
CellTiter-Blue Cell Viability Assay kit (Promega). Cells were
plated in 24-well plates and treatments were performed as
described above. At the end of the treatments, resazurin was
added to the media according to manufacturer’s instructions and
incubation was continued for 1 h. At the end of the incubation,
resorufin fluorescence was measured using a fluorescence plate
reader (BioTek Synergy HT Multi-Detection Microplate Reader)
at wavelengths, excitation 540 nm and emission 590 nm. Results
are presented as a percent of control cells.
HRE luciferase reporter assay
HEK 293A cells were plated in a 24-well plate and transiently
transfected with TG2 constructs together with a firefly luciferase
vector under control of HRE-bearing 64-mer fragment from
human enolase promoter [43] and Renilla luciferase vector [9] using
Fugene 6 reagent as described above. 24 h post-transfection, cells
were transferred to serum free media and placed in a hypoxic
environment for 16 h at 37uC as described above. Control cells
were kept in ambient oxygen concentrations under the same
conditions. Luciferase activity was measured in cellular lysates
using the Dual-Luciferase Reporter Assay System Kit (Promega,
Madison, WI, USA) according to the manufacturer’s protocol and
a TD-20/20 Luminometer. For each sample, the Firefly luciferase
data was normalized to the Renilla luciferase internal control.
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